Global Early Toxicity Testing Market - 2022-2029
本報告提供全球初期毒性實驗的市場調查，彙整市場定義和概要，新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素的分析，法律制度，市場規模的轉變·預測，各種區分·地區/各主要國家的明細，競爭環境，主要企業簡介等資訊。
The global early toxicity testing market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
Toxicity is the degree to which a substance endangers a living creature. During the production of newer molecules, the effects of chemical substances on the body are examined to select a possible therapeutic candidate. Early toxicity testing is performed at the pre-clinical phases of a drug development process. It is critical because toxicity is the top cause of prospective drug candidate failure in the later stages of drug development, resulting in substantial financial losses for companies.
The global early toxicity testing market is predicted to develop significantly over the forecast period, owing to increased R&D activities and strict regulatory bodies concerned with public healthcare welfare. Furthermore, technological developments in vitro approach, an increase in the application of in vitro models in the global early toxicity testing sector, and an increase in the adoption of early toxicity testing in various industries all contribute to market growth.
Rising awareness about early toxicity testing will drive the market growth
Preclinical toxicity testing investigations are conducted to evaluate the new chemical entity under development to analyze its safety and efficacy in animal models before entering human clinical trials.Approximately 30% of medications tried in clinical trials fail due to unexpected and unacceptable toxicological characteristics.Early toxicity diagnosis during the preclinical phase can save money on clinical studies and avoid needless hazardous chemical exposure to healthy human volunteers participating in clinical trials. As a result, industries participating in the medication development process and regulatory agencies focus on the early identification of chemical toxicity.To this end, toxicity investigations are outsourced to a CRO professional team to expedite the process and save expenses.As a result, the increased emphasis on early toxicity detection will likely boost the worldwide early toxicity testing market during the forecast period.
Furthermore, long-term growth patterns in this sector can be caught by maintaining ongoing process improvements and financial stability in order to invest in the finest tactics. Furthermore, technological advancements in in vitro methods, an increase in the usage of in vitro models in the worldwide early toxicity testing sector, and an increase in early toxicity testing in various industries all contribute to market growth. Leading players throughout the world are focusing their efforts on technological advancements in order to boost market growth. Technological advancements in early toxicity testing will generate chances for the early toxicity testing market to develop during the forecast period.These factors are likely to boost the Early Toxicity Testing market.
Difficulties associated with preclinical testing is likely to hamper the market growth
However, difficulties associated with preclinical testing impede the growth of the worldwide early toxicity testing market. Furthermore, firms conduct early toxicity testing to meet government regulations for marketing the drug, which is regarded as a growth restricting factor. The main cause of growth decline is a lack of awareness about the use of early toxicity.
COVID-19 Impact Analysis
The quick emergence of COVID-19 has significantly increased demand for the early toxicity testing sector. Toxicity testing examines if a substance is poisonous to living or non-living organisms. The process of determining the degree of tissue or cell damage and the ideal safe dose of any chemical or treatment is known as early toxicity testing. Scientists have discovered two new drugs to prevent COVID-19 infection and treat those exposed to the novel coronavirus. Peptide-based medicines developed by researchers at Australia's QIMR Berghofer Medical Research Institute are being tested in hamsters at IDMIT, a preclinical and clinical research facility in France. To boost vaccine effectiveness, the first peptide-based drug would be provided prior to viral exposure. The second treatment, on the other hand, would prevent the virus from spending time in previously infected cells. The peptide-based medications were discovered when researchers discovered a previously unknown method of entry for SARS-CoV-2, the virus that causes COVID-19.
The in vitro segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The section is separated into three different types based on technique: in vivo, in vitro, and silico. In 2020, the in vitro category was the greatest contributor to the early toxicity testing market, and it is predicted to maintain its dominance throughout the analysis period. In vitro toxicity approaches employ a variety of laboratory procedures and cell lines to examine the potentially detrimental effects of various medications and substances on human health. The cost-effectiveness of this technique, technical innovation, and tight regulations for animal use during diagnostic processes all contribute significantly to the growth of the early toxicity testing industry.
Furthermore, market growth is fueled by introducing new products into the market. For example, in Jan, 2018, Agilent Technologies Inc. has acquired Luxcel Biosciences, a provider of in vitro cell test kits based on real-time fluorescence plate readers situated in Cork, Ireland. This acquisition elevates Agilent's cell analysis line by including simple assay kits compatible with industry-standard plate-readers.As a result, various market players' number of regulatory authority approvals for products is boosting the market growth.
North America region holds the largest market share of the global early toxicity testing market
North America is the most important market for early toxicity testing. This can be linked to the USFDA's strict laws controlling product safety evaluation, significant R&D funds, the existence of top toxicology testing service provider CROs in the region, and strong consumer awareness about product safety.
In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, In February 2018, Charles River Laboratories Inc, an American company specializing in preclinical and clinical laboratory acquisitions, paid USD 800 million for MPI research. Furthermore, advancements in various early toxicity testing techniques from established key players, in the United States, are likely to drive the market growth in North America.
The early toxicity testing market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Agilent Technologies, Bruker Corporation, Eurofins Scientific, GE Healthcare, Thermo Fisher Scientific, Envigo, Merck , SGS, WuXi AppTec, Quest Laboratories, among others.
The key players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Early Toxicity Testing market globally. For instance, in February 2021, the ratings of QUEST Diagnostics Incorporated and other ratings pertaining to the same analytical unit have been reviewed by New York-Investor Moody's Service. At a portfolio review discussion on February 01,2021, Moody's assessed the adequacy of the ratings in light of the applicable primary methodology, recent events, and comparing the financial and operating characteristics to similarly rated peers.
GE Healthcare, a global leader in medical technology and digital solutions, helps doctors to make faster, more informed decisions with intelligent devices, data analytics, applications, and services powered by its Edison intelligence platform.
Cytiva: CytivaTM hESC-derived Cardiomyocyte toxicity assays from GE Healthcare and to uncover novel biological biomarkers for cardiotoxicity. The cooperation brings together Genentech's toxicology expertise, experience with primary cardiomyocytes, a library of reference drugs, and GE Healthcare's Cytiva Cardiomyocytes and IN Cell Analyzer high-content analysis (HCA)imaging system. So far, GE Healthcare's Cytiva Cardiomyocytes have been blind tested against 26 recognized drugs having preclinical and clinical cardiac discordances.
Visualize the composition of the global early toxicity testing market segmentation by technique, assay, end user, and region highlighting the key commercial assets and players.
Identify commercial opportunities in the global early toxicity testing market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global early toxicity testing market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global early toxicity testing market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 190 (approximate) pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Global Early Toxicity Testing Market- By Technique
Cell-Based ELISA and Western Blots
Enzyme Toxicity Assays
Bacterial Toxicity Assays
Tissues Culture Assays
Receptors Binding Assays
By Toxicity End Points and Tests
Skin Sensitization and Irritation
Global Early Toxicity Testing Market- By End User
Global Early Toxicity Testing Market- By Region
Middle East & Africa
LIST NOT EXHAUSTIVE